Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947258 | 0.91 | THRA (0.33) | ALDH1A1RAB9A | |
| SCHEMBL3458351 | 0.90 | TAAR1 (0.33) | TAAR1CYP4F2CYP4A11 | |
| SCHEMBL181016 | 0.86 | CA1 (0.32) | — | |
| SCHEMBL17529865 | 0.85 | LMNA (0.33) | AKT1 | |
| SCHEMBL17529864 | 0.84 | ALDH1A1 (0.38) | ALDH1A1TAAR1CYP4F2CYP4A11 | |
| SCHEMBL20478197 | 0.82 | NQO1 (0.35) | — | |
| SCHEMBL50701 | 0.82 | NQO1 (0.35) | — | |
| SCHEMBL8826417 | 0.82 | — | — | |
| SCHEMBL6659875 | 0.82 | — | — | |
| SCHEMBL2945242 | 0.82 | TDP1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106574116-B | Curable composition, cured product, method for using curable composition, and optical device | 琳得科株式会社 | 2020-07-14 | — | — | CN | disclosed |
| EP-2963088-B1 | CURABLE COMPOSITION, CURED PRODUCT, METHOD FOR USING CURABLE COMPOSITION, PHOTOELEMENT SEALING BODY AND METHOD FOR PRODUCING PHOTOELEMENT SEALING BODY | LINTEC CORP (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-2990112-B1 | METHOD FOR MANUFACTURING CATALYST FOR SYNTHESIZING CYCLIC CARBONATE | MARUZEN PETROCHEM CO LTD (JP) | 2020-03-25 | — | — | EP | disclosed |
| EP-2990113-B1 | METHOD FOR PRODUCING CATALYST FOR CYCLIC CARBONATE SYNTHESIS | MARUZEN PETROCHEM CO LTD (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-10266734-B2 | Curable composition, cured product, method for using curable composition, and optical device | LINTEC CORPORATION (JP) | 2019-04-23 | — | — | US | disclosed |
| EP-3187547-B1 | CURABLE COMPOSITION, CURED PRODUCT, METHOD FOR USING CURABLE COMPOSITION, AND OPTICAL DEVICE | LINTEC CORP (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-10029241-B2 | Method for producing catalyst for cyclic carbonate synthesis | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10011621-B2 | Method for producing silica gel-immobolized phosphonium salt catalysts | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-9834536-B2 | Method for producing catalyst for cyclic carbonate synthesis | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9783715-B2 | Curable composition, cured product, method for using curable composition, photoelement sealing body and method for producing photoelement sealing body | LINTEC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-8703880-B2 | Curable composition, cured product, and method for using of curable composition | LINTEC CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8507044-B2 | Molding material composed of polyorganosiloxane compound, sealing material, and sealed optical device | LINTEC CORPORATION (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20130035455-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR USING OF CURABLE COMPOSITION | LINTEC CORPORATION (JP) | 2013-02-07 | — | — | US | disclosed |
| CN-102906198-A | Curable composition, cured product, and method for using curable composition | LINTEC CORP | 2013-01-30 | — | — | CN | disclosed |
| US-8357261-B2 | Adhesive mainly composed of polyorganosiloxane compound | LINTEC CORPORATION (JP) | 2013-01-22 | — | — | US | disclosed |
| EP-2546306-A1 | CURABLE COMPOSITION, HARDENED MATERIAL, AND METHOD FOR USING CURABLE COMPOSITION | LINTEC Corporation (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20110054139-A1 | ADHESIVE MAINLY COMPOSED OF POLYORGANOSILOXANE COMPOUND | LINTEC CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110034659-A1 | MOLDING MATERIAL COMPOSED OF POLYORGANOSILOXANE COMPOUND, SEALING MATERIAL, AND SEALED OPTICAL DEVICE | LINTEC CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-7759406-B2 | Process for producing polysilsesquioxane graft polymer, pressure-sensitive adhesive, and pressure-sensitive adhesive sheet | LINTEC CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20080051487-A1 | Process for Producing Polysilsesquioxane Graft Polymer, Pressure-Sensitive Adhesive, and Pressure-Sensitive Adhesive Sheet | LINTEC CORPORATION (JP) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029241-B2 | Method for producing catalyst for cyclic carbonate synthesis | CYCS, CA7, CA9 | AKT1 1437/4885ALDH1A1 3770/4885RAB9A 2887/4885 |
| US-10011621-B2 | Method for producing silica gel-immobolized phosphonium salt catalysts | SIK2, SIK3, SIK1 | AKT1 147/4885ALDH1A1 4167/4885RAB9A 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.